CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

Program Description

The use of chimeric antigen receptor (CAR)-modified T-cell therapies for hematologic malignancies is rapidly expanding. Although CD19-directed CAR T-cell therapies have shown great promise in improving patient outcomes and have been incorporated into guidelines for the treatment of relapsed and refractory lymphoma, use remains limited by the potential to cause life-threatening toxicities as well as cost. With emerging data on indications for therapy and financial regulations for CAR T-cell therapy, managed care professionals are challenged to make CAR T-cell therapy more accessible for patients. This article will explore FDA-approved indications of CD19-directed CAR T-cell therapies, focusing on data for second-line therapy in large B-cell lymphoma and the management of CAR T-cell‒related toxicities. Managed care professionals and pharmacists involved in the care of patients with lymphoma will gain insight to expand their roles in the management of serious toxicities as well as the costs associated with CAR T-cell treatment to ensure provision of cost-effective, patient-centered care.

Target audience: Managed care and oncology pharmacists

Type of activity: Application
Release date: October 28, 2022
Expiration date: March 31, 2024

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore recent evidence supporting the use of chimeric antigen receptor (CAR)-modified T-cell therapies in lymphoma
• Interpret the guideline recommendations for implementation of CAR T-cell therapy in treatment pathways and management of associated adverse effects
• Identify the value and access considerations for CAR T-cell therapy indicated for the treatment of lymphomas

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-534-H01-P. The activity is available for CE credit through March 31, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: Omeros
Advisory board participation: Omeros, Incyte, BMS, Seagen, Merck

Medical Writer

Shetal S. Desai, PharmD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Medical reviewer Ryan Haumschild, PharmD, MS, MBA, has the following relevant financial relationship with commercial interest to disclose:
Grant/Research Support: GlaxoSmithKline

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms